ArticleDrugs - real world outcomes2026
Effectiveness and Safety of PD-1 Inhibitor Rechallenge After Prior Immunotherapy in Patients Aged ≥ 60 Years with Advanced Non-Small-Cell Lung Cancer: A Single-Center Retrospective Study.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesEvidence regarding the effectiveness and safety of PD-1 inhibitor rechallenge in older patients with advanced non-small-cell lung cancer (NSCLC) previously exposed to immunotherapy remains limited. This study evaluated the effectiveness and safety of PD-1 inhibitor monotherapy rechallenge in patients aged ≥ 60 years with advanced NSCLC who had previously received immunotherapy.
methodsThis single-center retrospective cohort study included 56 patients aged ≥ 60 years with advanced NSCLC who received PD-1 inhibitor monotherapy rechallenge at the Department of Oncology Radiotherapy at the Guilin People's Hospital between January 2019 and March 2025. Objective response rate (ORR) and disease control rate (DCR) were assessed per RECIST 1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method. Treatment-related adverse events (TRAEs) were graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
resultsIn the full analysis population of 56 patients with five non-evaluable patients counted as non-responders, the ORR and DCR were 21.4% and 58.9%, respectively. The median PFS of the 56 older patients with advanced NSCLC receiving PD-1 inhibitors was 3.9 months (95% CI 1.88-5.92) and median OS was 11.3 months (95% CI 4.78-17.82) from rechallenge of PD-1 inhibitors. The safety profile indicated that TRAEs of any grade occurred in 41 patients (73.2%), most commonly fatigue, decreased appetite, rash, hepatic enzyme elevations, pneumonitis, and hypothyroidism. Grade ≥ 3 TRAEs were detected in 15 patients (26.8%). Immune-related TRAEs were generally manageable with corticosteroids and supportive care.
conclusionPD-1 inhibitor rechallenge showed modest antitumor activity and a generally manageable safety profile in this selected cohort of patients aged ≥ 60 years with advanced NSCLC previously exposed to immunotherapy. Given the small sample size, single-center retrospective design, and potential selection bias, these findings should be considered preliminary and require validation in larger multicenter prospective studies.
Identifiers
42667576What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.